BridgeBio have significantly boosted this development of an new therapy for cardiac amyloidosis, employing the investigational drug. Early clinical information indicates promising outcomes for patients diagnosed by the https://biotech386606.blogitright.com/42463926/company-advances-attr-cm-treatment-through-the-therapy